Login / Signup

Amide-functionalized 1,2,4-Triazol-5-amines as Covalent Inhibitors of Blood Coagulation Factor XIIa and Thrombin.

Lukas ImbergSimon PlatteCatharina ErbacherConstantin Gabriel DaniliucSvetlana A KalininaWolfgang DörnerAntti PosoUwe KarstDmitrii V Kalinin
Published in: ACS pharmacology & translational science (2022)
To counteract thrombosis, new safe and efficient antithrombotics are required. We herein report the design, synthesis, and biological activity of a series of amide-functionalized acylated 1,2,4-triazol-5-amines as selective inhibitors of blood coagulation factor XIIa and thrombin. The introduction of an amide moiety into the main scaffold of 3-aryl aminotriazoles added certain three-dimensional properties to synthesized compounds and allowed them to reach binding sites in FXIIa and thrombin previously unaddressed by non-functionalized 1,2,4-triazol-5-amines. Among synthesized compounds, one quinoxaline-derived aminotriazole bearing N -butylamide moiety inhibited FXIIa with the IC 50 value of 28 nM, whereas the N -phenylamide-derived aminotriazole inhibited thrombin with the IC 50 value of 41 nM. Performed mass-shift experiments and molecular modeling studies proved the covalent mechanism of FXIIa and thrombin inhibition by synthesized compounds. In plasma coagulation tests, developed aminotriazoles showed anticoagulant properties mainly affecting the intrinsic blood coagulation pathway, activation of which is associated with thrombosis but is negligible for hemostasis.
Keyphrases
  • quantum dots
  • pulmonary embolism
  • photodynamic therapy
  • atrial fibrillation
  • high resolution